Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.38 |
| ▸ | CNR1 | P21554 | 8/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25733242 | 1.00 | CNR2 (0.38) | CNR2CNR1PIK3CAMTORPIK3CG | |
| SCHEMBL25733537 | 0.86 | KDM4E (0.38) | CNR2PIK3CAPDE10AKDM4EALDH1A1 | |
| SCHEMBL31730977 | 0.86 | KDM4E (0.38) | CNR2PIK3CAPDE10AKDM4EALDH1A1 | |
| SCHEMBL31730946 | 0.85 | CNR2 (0.43) | CNR2CNR1PDE10AKDM4EALDH1A1 | |
| SCHEMBL25733331 | 0.85 | CNR2 (0.43) | CNR2CNR1PDE10AKDM4EALDH1A1 | |
| SCHEMBL31730846 | 0.85 | KDM4E (0.45) | CNR2PIK3CAPDE10AKDM4EALDH1A1 | |
| SCHEMBL25733517 | 0.85 | KDM4E (0.45) | CNR2PIK3CAPDE10AKDM4EALDH1A1 | |
| SCHEMBL25276103 | 0.84 | KDM4E (0.44) | CNR2PDE10AKDM4EALDH1A1HPGD | |
| SCHEMBL25281801 | 0.84 | LMNA (0.48) | CNR2CNR1PIK3CAMTORPDE10A | |
| SCHEMBL31730882 | 0.84 | PIK3CA (0.41) | CNR2CNR1PIK3CAMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | TDP1, TDP2, PIKFYVE | CNR2 4215/4885CNR1 4210/4885PIK3CA 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.